Piramal Pharma (NSE:PPLPHARMA) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
51 GF Score
Price ₹209.55
GF Value ₹187.26
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Piramal Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Piramal Pharma Quality Rank Related Terms

NSE:PPLPHARMA
51GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued. The current stock price of ₹209.55 is trading 11.9% above its estimated GF Value™ of ₹187.26. GuruFocus considers Piramal Pharma to be Modestly Overvalued.

Key valuation signals for NSE:PPLPHARMA:

  • Quality Rank:
  • GF Value™: ₹187.26 vs. price of ₹209.55 (11.9% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score

Get the complete analysis for NSE:PPLPHARMA

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹209.55
Price
₹187.26
GF Value